New drug may extend remission in tough lung cancer
NCT ID NCT07559786
First seen May 13, 2026 · Last updated Jun 09, 2026 · Updated 5 times
Summary
This study tests whether adding adebrelimab (an immunotherapy) after standard chemoradiotherapy can help keep limited-stage small cell lung cancer from coming back. About 200 adults with untreated, limited-stage disease will receive either standard treatment alone or standard treatment followed by adebrelimab maintenance. The goal is to see if the drug improves how long people live without their cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.